ArticlesPalbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
Introduction
Hormone-receptor-positive breast cancer represents the largest subset of this disease, affecting more than 1 million patients annually worldwide.1 A fundamental component of systemic therapy for hormone-receptor-positive early breast cancer is adjuvant endocrine therapy, which provides substantial benefits by reducing disease recurrence and the risk of death from breast cancer.2, 3 However, despite improvements in adjuvant endocrine therapy, including the use of aromatase inhibitors, extended duration of therapy, and luteinising hormone-releasing hormone (LHRH) agonists in premenopausal patients, considerable risk of recurrence persists over several decades.4
Loss of control of the cell cycle is a hallmark of malignancy, including in hormone-receptor-positive breast cancer.5 A well accepted mechanism associated with cell-cycle progression in hormone-receptor-positive breast cancer is overexpression of cyclin D or other alterations, or both, leading to phosphorylation of the retinoblastoma protein and unregulated passage from the G1 to S phase of the cell cycle. Inhibitors of cyclin dependent kinases 4 and 6 (CDK4/6) result in hypophosphorylation of the retinoblastoma protein and re-establishment of control of the G1/S transition.6, 7
The combination of a CDK4/6 inhibitor with endocrine therapy has shown antitumour activity by prolonging progression-free survival and overall survival in the first-line and subsequent-line settings of metastatic hormone-receptor-positive, HER2-negative breast cancer, with an acceptable side-effect profile. Currently, three CDK4/6 inhibitors, including palbociclib, are approved for these indications,8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and are considered standard of care in both first-line and pre-treated settings.18, 19 The toxicity profile of palbociclib is well described, and is notable for reversible neutropenia that is typically not associated with serious infections. Aside from the presence of the oestrogen receptor in hormone-receptor-positive breast cancer, there are no currently approved biomarkers for the selection of CDK 4/6 inhibitors.
Based on the broad activity of CDK4/6 inhibitors for treatment of metastatic breast cancer, as well as the need to further reduce the risk of recurrence in the early setting, the phase 3 PALLAS trial was designed to investigate whether the addition of palbociclib to adjuvant endocrine therapy improves outcomes compared with endocrine therapy alone in patients with hormone-receptor-positive, HER2-negative early breast cancer.
Section snippets
Study design and participants
PALLAS is an international, multicentre, open-label, randomised, phase 3 study investigating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with hormone-receptor-positive, HER2-negative early breast cancer. The trial was open to accrual at 406 cancer centres in 21 countries: Australia, Austria, Belgium, Canada, Germany, Hungary, Ireland, Israel, Italy, Japan, Mexico, Poland, Portugal, South Korea, Spain, Sweden, Switzerland, Taiwan, the Netherlands,
Results
Between Sept 1, 2015, and Nov 30, 2018, 5760 patients were randomly assigned to a treatment group and are included in the intention-to-treat population (figure 1). The present analysis included 1013 patients with stage IIA disease enrolled up to Sept 26, 2017. Patient characteristics are shown in table 1. The median age was 52 years (IQR 45–61) and 4729 (82·1%) of 5760 patients had stage IIB or III tumours. 4754 (82·5%) of 5760 patients had received adjuvant or neoadjuvant chemotherapy before
Discussion
In this second interim analysis of the PALLAS trial, the addition of palbociclib to adjuvant endocrine therapy did not improve invasive disease-free survival compared with endocrine therapy alone in patients with stage II–III hormone-receptor-positive, HER2-negative breast cancer. This analysis was done after 67% of expected invasive disease-free survival events had occurred, and a futility boundary had been crossed. In the treatment group, 42% of patients stopped palbociclib prematurely,
Data sharing
Pseudonymised individual participant data will be made available after completion of the study (ie, at the end of the follow-up phase) at the latest; the specific data made available will depend on the data needed to answer the question in the application. Other documents that will be available include the master informed consent form, the study protocol and amendments, and the PALLAS Policy for Access to Study Data or Surplus Samples for Research Projects not related to the protocol (policy).
References (31)
- et al.
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Lancet Oncol
(2016) - et al.
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis
Lancet Oncol
(2019) - et al.
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Ann Oncol
(2018) - et al.
Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature
Cancer Treat Rev
(2012) Mechanisms governing metastatic dormancy and reactivation
Cell
(2013)- et al.
CDK4/6 inhibitors: the mechanism of action may not be as simple as once thought
Cancer Cell
(2018) - et al.
Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study
JAMA Oncol
(2019) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
Lancet
(2005)- et al.
Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update
J Clin Oncol
(2019) - et al.
20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years
N Engl J Med
(2017)
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Breast Cancer Res
Treating cancer with selective CDK4/6 inhibitors
Nat Rev Clin Oncol
Are all cyclin-dependent kinases 4/6 inhibitors created equal?
NPJ Breast Cancer
Palbociclib and letrozole in advanced breast cancer
N Engl J Med
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
N Engl J Med
Cited by (174)
The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility
2023, Critical Reviews in Oncology/HematologyEfficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2− breast cancer: an umbrella review
2025, Journal of Cancer Research and Clinical Oncology
- †
Joint last authors